Close Menu

This article has been updated with additional information from Centogene's earnings call.

NEW YORK – Centogene on Thursday morning reported a 52 percent year-over-year increase in Q4 revenues, driven by its pharmaceutical business, and a 21 percent increase in revenues for 2019.

"To date, we have been able to operate our business throughout this crisis without too much disruption," said Centogene CEO Arndt Rolfs during a conference call to discuss the financial results, commenting on the COVID-19 pandemic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.